Onco Actu du 17 janvier 2020

	1.4 BIOLOGIE - TECHNOS, MODÈLES
VUMC study sheds light on gastric cancer development [VUMC] Researchers at Vanderbilt University Medical Center have created the world’s first laboratory model of precancerous changes in the lining of the stomach, a scientific tour de force that is helping to unlock the mysteries of gastric cancer development.
	2.6 ETIOLOGIE - ENVIRONNEMENT
Bayer close to Roundup settlement, mediator tells Bloomberg [Reuters] Feinberg was quoted as saying that the number of cases had grown to between 75,000 and 85,000 and “maybe more”. Bayer in October said it was now facing 42,700 U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products [CDC] Vitamin E acetate is strongly linked to the EVALI outbreak. Vitamin E acetate has been found in product samples tested by FDA and state laboratories and in patient lung fluid samples tested by CDC from geographically diverse states. Vitamin E acetate has not been found in the lung fluid of people that do not have EVALI.
	4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
Illumina Targets Single-Cell, Oncology Applications With New NextSeq Platform [Genome Web] Some applications that Illumina hopes will drive customers to the platform include single-cell sequencing, whole-genome sequencing, liquid biopsy, and comprehensive cancer panels.
	5. TRAITEMENTS
Immune Checkpoint Inhibitors Associated with Lower Risk of Developing Severe and Any Adverse Events Compared to Chemotherapy [ESMO] Results from the largest and most comprehensive meta-analysis across multiple primary solid tumours.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Hormone resistance in breast cancer linked to DNA ‘rewiring’ [Garvan Institute] Garvan researchers have revealed changes to the 3D arrangement of DNA linked to treatment resistance in ER+ breast cancer.
New Nanoparticle Therapy Appears More Effective Than Standard Therapy at Treating Aggressive Breast Cancer [University of Maryland] Experimental Nanoformulation Outperforms FDA-Approved Treatment for Metastatic Breast Cancer, Increasing Survival in Animal Studies.
	5.10 TRAITEMENTS - ESSAIS
Maintenance Therapy with CC-486 Extends Survival of Adults with AML [NCI] In the new study, CC-486 was tested as a maintenance therapy for adults with AML that was in remission (meaning there were no signs of cancer) after receiving aggressive chemotherapy.
	5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS
After IPO, BioNTech nabs cell therapy startup Neon Therapeutics [Fierce Biotech] Neon sequences patients' tumors to identify neoantigens. Its program, NEO-PV-01, is made using synthetic peptides that mimic neoantigens found in each patient’s tumor cells.
Cancer Drug Developer BioNTech to Buy Neon Therapeutics in $67M Deal [Xconomy] With the no new investment going into cancer vaccines, Neon’s most advanced program is NEO-PTC-01, a personalized T cell therapy candidate that targets neoantigens on a patient’s tumors. That program is preclinical but is being prepared for human tests in Europe.
BioNTech rescues cancer biotech Neon in bargain buyout [Biopharma Dive] BioNTech will be carrying forward Neon's research, which is now headlined by a personalized T cell therapy and an earlier stage cell treatment targeting cancers with RAS mutations.
	5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
Cancers engaged in evolutionary arms race with immune system [Institute of Cancer Research] In the new study, the researchers analysed in minute detail the genetic landscape of four tumours from the stomach and gullet which had a fault in one or more important DNA repair genes – making them ‘hyper-mutated’.
	5.12.7 IMMUNOTHÉRAPIES - VACCINS
How Moderna is using Amazon cloud to produce personalized cancer vaccines [CNBC] In an interview with CNBC’s Jim Cramer, Bancel explained how Amazon Web Services — the fastest-growing division in Amazon — is playing a central role in the research to build medicines for infectious and rare diseases and cancer.
	5.2.1 PHARMA - PARTENARIATS
Pfizer teams up with Insilico to mine data for drug targets [Fierce Biotech] How valuable machine learning currently is to drug R&D remains a topic of debate, but Insilico has done more than most to try to validate the concept, including through the publication of details of its discovery of DDR1 kinase inhibitors in 21 days.
	5.3 TRAITEMENTS - FDA, EMA,...
FDA Offers Q&As on Submission of iPSPs for Cancer Drugs [RAPS] To help address a number of industry questions, the US Food and Drug Administration (FDA) on Wednesday published a new draft guidance on the submission of initial pediatric study plans (iPSPs) for oncology drugs.
The FDA: Faster, but not necessarily better. And that could threaten the agency's brand [EndPoints] To accommodate the higher volume of drug manufacturers, the FDA in 1992 was granted the power to collect fees for their reviews. Now, the annual fees collected under Prescription Drug User Fee Act (PDUFA) have jumped from $29 million in 1993 to $908 million in 2018, the data showed.
	5.4.1 TRAITEMENTS - ECONOMIE - NICE
Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund [NICE] Palbociclib joins 2 other NICE-approved drugs – ribociclib and abemaciclib – at this stage of treatment.
	5.4.2 TRAITEMENTS - ECONOMIE - IQWIG
German drug assessment body not convinced by Bayer's cancer drug Vitrakvi [Reuters] IQWiG - an independent authority that evaluates new drugs and plays an advisory role over what price German health services pay for them - in particular criticized the fact that the clinical trials lacked a comparative group that did not receive Vitrakvi.
Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient for derivation of an added benefit [IQWIG] "Like the Canadians, who have recently denied regular reimbursement of larotrectinib, or our English colleagues, who are currently discussing the multiple challenges in the benefit assessments of these types of drugs in the British Medical Journal, we see the lack of suitable data as the main obstacle to making adequate assessments.”
	6.4 MÉDICO-ÉCO
Comparing cancer costs is challenging, despite new price transparency rules [UNC Lineberger] Comparison shopping for airfare, a TV, or a car can be straightforward online. The same cannot be said for checking what hospitals charge for a standard radiation treatment for prostate cancer, according to a report published in JAMA Oncology.
'List price' for healthcare treatments in the U.S. may be misleading [Reuters] “Information on price does not reflect the true cost of care, nor does it reflect the charges sent to a patient on a bill. Obtaining the true cost of care and the potential financial impact on a patient remains elusive despite price transparency.”
What Can We Do To Lessen Financial Hardship As A Side Effect Of Cancer Care? [Dr. Len] We need solutions that work, for everyone. However, first we need understanding that these problems are real, that they impact everyday people every day, and that until we can fix this system we won’t be able to achieve the improvements in cancer care for everyone that are available to us right now.
	6.6 PUBLICATIONS
New AACR Journal, Blood Cancer Discovery, Publishes Its First Paper [AACR] Study reports the landscape of mutations present in pediatric acute lymphoblastic leukemia (ALL) and how this landscape changes during treatment, leading to relapse.
	6.7 DMP, BIG DATA & APPLIS
Eleven tips for working with large data sets [Nature] Big data are difficult to handle. These tips and tricks can smooth the way.
	6.7.3 DMP
Why Aren’t More Patients Electronically Accessing Their Medical Records (Yet)? [Health Affairs] It’s time to make a dramatic shift to a world in which patient data is no longer a closely held business asset, but a private (for use by the individual!) and public good. This is an effort many decades in the making, and it is worth doubling down on, right now.